ACPU
ACOR

Arrowgrass Capital Partners (US)’s Acorda Therapeutics ACOR Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-208
Closed -$661K – 454
2016
Q1 		$661K Buy
+208
New +$863K 0.01% 337
2015
Q4 		– Sell
-167
Closed -$530K – 480
2015
Q3 		$530K Buy
+167
New +$648K 0.01% 394
2014
Q4 		– Sell
-333
Closed -$1.35M – 484
2014
Q3 		$1.35M Buy
+333
New +$1.25M 0.03% 206

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ACOR Position: Q2 2016 in Review

Arrowgrass Capital Partners (US) sold out of Acorda Therapeutics (ACOR) in Q2 2016, closing a stake of 208 shares — an estimated $661K sold.

Arrowgrass Capital Partners (US) first reported a position in ACOR in Q3 2014 and held it in 3 quarters. The position peaked at $1.35M in Q3 2014. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2016.

  • Arrowgrass Capital Partners (US) reported no remaining Acorda Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 208 Acorda Therapeutics shares in Q2 2016, an estimated $661K.
  • Arrowgrass Capital Partners (US) first reported a position in Acorda Therapeutics in Q3 2014 and held it in 3 quarters.
  • Arrowgrass Capital Partners (US)'s Acorda Therapeutics position peaked at $1.35M in Q3 2014.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2016.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2016, filed 15 Aug 2016.